Optimer Pharmaceuticals Articles

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America

4 December 2012

Optimer Pharma to sell remaining stake in Optimer Biotech for $60 million

8 October 2012

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out

6 July 2012

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe

11 June 2012

Senior exec changes actual or sought at Johnson & Johnson, AstraZeneca and Optimer

10 April 2012

Optimer Pharma could earn $90 million from new Astellas deal

30 March 2012

Astellas and Optimer’s C. difficile drug cleared in Europe

13 December 2011

Optimer/Cubist’s Dificid poised to challenge Vancocin usage in C. difficile treatment; report

14 September 2011

US FDA approves Optimer’s Dificid for C. difficile infection

31 May 2011

Highlights from Digestive Disease Week

11 May 2011

US FDA advisory panel backs Optimer novel antibiotic Dificid for CDI

7 April 2011

Astellas to pay as much as 165 million euros for right to Optimer’s antibiotic fidaxomicin

8 February 2011

Optimer Pharma' fidaxomicin MA accepted for review by European Medicines Agency

20 August 2010

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end